Dr. Cohen Discusses Combination Therapy in MCL

Video

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses combination therapy for patients with mantle cell lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses combination therapy for patients with mantle cell lymphoma (MCL).

There is a lot of interest in incorporating novel treatments into the management of patients with MCL, Cohen says. This includes the possibility of eliminating chemotherapy in the frontline setting. There are mature data suggesting that rituximab (Rituxan) plus lenalidomide (Revlimid) will induce a prolonged remission in patients with MCL. Although patients may have to stay on this combination for a long period of time, Cohen says that the toxicities seem tolerable.

Cohen says that combinations with novel agents are likely going to be the future of MCL treatment. While cytarabine is felt to be an important part of the chemotherapy backbone, it does not work for all patients. For example, patients with TP53 mutations do not respond well to cytarabine-based intensive therapy. For those patients, Cohen says that novel combinations are under investigation.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.